The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...

Hims & Hers Health will continue offering low-cost compounded weight-loss shots even after Novo Nordisk terminated their partnership over alleged “deceptive marketing,” CEO Andrew Dudum said in his ...

We recently published Market on Mute? Not for These 10 Stocks With Surprising Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is ...

Hims & Hers Health is a top telehealth company with strong growth, innovation, and global expansion plans. See more on HIMS ...

Hims & Hers Health delivered a first quarter that surpassed Wall Street’s expectations, driven by strong adoption of its ...

Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE: NVO ), which ended in June 2025, in an interview with The ...

Andrew Dudum is a disrupter. In 2017 he founded Hims & Hers (NYSE: HIMS), a digital health startup with the goal of upending the traditional healthcare market.

Investors, CEOs and commentators trashed Hims & Hers founder and CEO Andrew Dudum on social media Wednesday after he praised the "moral courage" of the anti-Israel protesters creating havoc on ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Kevin O'Leary sounded off on Hims & Hers CEO Andrew Dudum over his initial support of the anti-Israel protests and said he would have been fired in seconds if he worked for him.